ABSTRACT
Various immune-related adverse events (irAEs), including fulminant type 1 diabetes (FT1D), are known to be associated with immune checkpoint inhibitors (ICIs). We experienced two lung adenocarcinoma cases who developed fulminant type 1 diabetes long after discontinuation of ICI therapies. One, a 74-year-old male, received nivolumab and developed fulminant type 1 diabetes 44 days after the last infusion. The other, an 85-year-old male, received atezolizumab and developed fulminant type 1 diabetes 171 days after the last infusion. Clinical ICI treatment guidelines recommend laboratory tests during ICI treatments but the necessity of tests in patients whose ICI therapy has been discontinued is not clearly described. These cases indicate that blood glucose monitoring should be continued at least for several months, and that patients should be informed of the possibility of fulminant type 1 diabetes after ICI discontinuation, because fulminant type 1 diabetes progresses rapidly and can be life-threatening if not promptly recognized.
Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Diabetes Mellitus, Type 1 , Immune Checkpoint Inhibitors , Lung Neoplasms/drug therapy , Nivolumab/adverse effects , Aged , Aged, 80 and over , Blood Glucose , Blood Glucose Self-Monitoring , Diabetes Mellitus, Type 1/chemically induced , Humans , Immune Checkpoint Inhibitors/adverse effects , Lung Neoplasms/complications , MaleSubject(s)
Diabetes Mellitus, Type 2/complications , Hamstring Muscles/diagnostic imaging , Infarction/diagnostic imaging , Quadriceps Muscle/diagnostic imaging , Biopsy , C-Reactive Protein/metabolism , Creatine Kinase/metabolism , Diabetic Nephropathies/etiology , Diabetic Nephropathies/therapy , Diabetic Retinopathy/etiology , Diagnosis, Differential , Fever/etiology , Hamstring Muscles/blood supply , Humans , Infarction/etiology , Infarction/metabolism , Infarction/pathology , Kidney Failure, Chronic/etiology , Kidney Failure, Chronic/therapy , Magnetic Resonance Imaging , Male , Middle Aged , Muscle, Skeletal/blood supply , Muscle, Skeletal/diagnostic imaging , Muscle, Skeletal/pathology , Pyomyositis/diagnosis , Quadriceps Muscle/blood supply , Quadriceps Muscle/pathology , Renal Dialysis , ThighABSTRACT
CONTEXT: Tumors producing IGF-2 (IGF-2oma) are a major cause of spontaneous hypoglycemia. The treatment mainstay is surgical resection. Many case reports note resolution of hypoglycemia after IGF-2oma resection; however, outcomes are variable according to tumor type. We report a case of resolving hypoglycemia, observed on continuous glucose monitoring, after resection of an IGF-2-producing solitary fibrous tumor of pleura and review the current literature. CASE REPORT: A 69-year-old woman presented with impaired consciousness because of hypoglycemia. An IGF-2oma was diagnosed as the cause for hypoglycemia because of decreased serum insulin and IGF-1, the presence of a pleural tumor, and a high-molecular-weight form of serum IGF-2 detected by Western immunoblot. Surgical resection was performed; pathological examination demonstrated a solitary fibrous tumor with low-grade malignancy. Continuous glucose monitoring showed reversal of hypoglycemia after tumor resection. Approximately 2 years after resection, the patient has no signs of tumor recurrence or hypoglycemia. CONCLUSIONS: An IGF-2-producing solitary fibrous tumor of pleura in this case caused hypoglycemia. From a search of the literature of 2004-2014, 32 cases of IGF-2oma with hypoglycemia that underwent radical surgery were identified; in 19 (59%) patients, hypoglycemia was reversed, and there was no subsequent recurrence. The remaining 13 (41%) patients experienced tumor recurrence or metastasis an average of 43 months after initial tumor resection. The tumor of the present case was a low-grade malignancy. Regular follow-up with biomarker monitoring of glucose metabolism and assessment of hypoglycemic symptomatology, in conjunction with imaging tests, is important for detecting possible tumor recurrence and metastasis.
